Skip to main content

Table 2 Incidence of local and systemic reactions reported for the two vaccine groups

From: Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects

  

Sub/MF59™ %(n)

Subunit %(n)

Local reaction

Rash

0.0(0)

0.5(1)

 

Erythema

1.5(6)

1.5(3)

 

Induration

0.5(2)

2.5(5)*

 

Swelling

2.8(11)

1.0(2)

 

Pain

10.2(40)**

3.0(6)

 

Pruritus

1.3(5)

3.0(6)

Systemic reaction

Headache

3.6(14)

2.5(5)

 

Fever

15.9(62)**

7.6(15)

 

Tiredness

3.3(13)

1.0(2)

 

Diarrhoea

0.8(3)

2.0(4)

 

Vomiting

1.0(4)

1.0(2)

 

Myalgia

1.8(7)

0.5(1)

 

Cough

2.0(8)

2.0(4)

 

Angina

1.5(6)

1.0(2)

 

Watery nasal discharge

1.0(4)

1.0(2)

 

Skin disease (e.g. eczema)

0.0(0)

1.0(2)

 

Irritability

0.0(0)

0.5(1)

  1. *P < 0.05 versus the Sub/MF59™ vaccine group; **P ≤ 0.005 versus the Subunit vaccine group
  2. Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine